MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
BLU - Bellus Health Inc
$3.89
-0.14(-3.47%)9:00:01 PM 3/2/2021
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    03/1/2021BLU
    Travelers are looking for 'safe, outdoor, open spaces' when planning their next vacation: SimilarWeb's Alisha Kapur

    Alisha Kapur, SimilarWeb's lead travel industry consultant, joined Yahoo Finance Live to discuss the latest travel industry trends.

    02/25/2021BLU
    BELLUS Health Reports Year 2020 Financial Results and Business Highlights

    BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ending December 31, 2020.

    02/22/2021BLU
    BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

    BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences.

    02/18/2021BLU
    IIROC Trade Resumption - BLU

    18, 2021 /CNW/ - Trading resumes in: Company: BELLUS Health Inc.TSX Symbol: BLU All Issues: NoResumption (ET): 12:54 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.

    02/18/2021BLU
    IIROC Trading Halt - BLU

    18, 2021 /CNW/ - The following issues have been halted by IIROC: Company: BELLUS Health Inc.TSX Symbol: BLU All Issues: NoReason: Single-Stock Circuit BreakerHalt Time (ET): 12:49 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.

    02/18/2021BLU
    2 “Strong Buy” Penny Stocks That Could Rally Over 100%

    Bank of America has a strong reputation for keeping finger on the pulse of the financial world – and one of its key tools is the Global Fund Manager Survey, conducted monthly and seeking opinions from more than 200 hedge fund, mutual fund, and pension fund managers who hold a combined $645 billion in AUM. It’s the largest regularly conducted survey of its kind. And BofA most recent findings show that Big Money is feeling confident. More than 90% of investors surveyed believe that 2021 will show ...

    01/15/2021BLU
    Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

    01/14/2021BLU
    BELLUS Health to Present at the Eleventh International Virtual Cough Symposium

    BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Dr. Catherine Bonuccelli, M.D., BELLUS Health's Chief Medical Officer, and Dr. Denis Garceau, Ph.D., Bellus Health’s Senior Vice President of Drug Development, will be presenting data on BLU-5937 at the Eleventh International Virtual C...

    12/23/2020BLU
    BELLUS Health Establishes At-the-Market Facility

    BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), announces that it has entered today into an agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") pursuant to which the Company may from time to time in the future sell, through at-the-market distributions with Jefferies acting as sales agent, such common shares as would have an aggregate offer price of up to US$50.0 million, including sales made directly on the Nasdaq Global Market ("Nasdaq") or on any oth...